Are cognitive deficits more severe among people with treatment-resistant schizophrenia than treatment responders?
Saved in:
| Title: | Are cognitive deficits more severe among people with treatment-resistant schizophrenia than treatment responders? |
|---|---|
| Authors: | Koloth, Ananthakrishnan (AUTHOR), Yeak, Kim (AUTHOR), Azimi, Somayyeh (AUTHOR), Koloth, Radhakrishnan (AUTHOR), Alexander, Aneeka (AUTHOR), Dragovic, Milan (AUTHOR), John, Alexander Panickacheril (AUTHOR) |
| Source: | Australasian Psychiatry. Apr2026, Vol. 34 Issue 2, p162-168. 7p. |
| Subjects: | Schizophrenia, Cognition disorders, Executive function, Short-term memory, Cognitive processing speed, Clozapine |
| Abstract: | Background: Given the robust association of cognitive deficits (CD) with community functioning in people with schizophrenia and the inconsistent findings from the limited research on CD among people with treatment-resistant schizophrenia (TRS), we evaluated the neurocognitive functions of patients with TRS. Methods: We retrospectively collated data on cognition and selected demographic and clinical variables of 181 patients with TRS and 59 with treatment-responsive schizophrenia (non-TRS) admitted to a psychiatric rehabilitation facility from 2010 to 2019. The Brief Assessment of Cognition in Schizophrenia (BACS) was used to evaluate cognitive function. Multivariate analysis was utilised to compare the BACS scores of the two groups. Results: TRS patients had more severe CD than non-TRS patients, with the BACS composite score (p =.003), verbal memory and learning (p =.003), working memory (p =.043), and psychomotor speed (p =.004) significantly worse in the TRS group. There was no significant difference in the BACS scores between the 60% of the TRS patients who were treated with clozapine and the TRS patients (40%) treated with other antipsychotics. Conclusion: CD are more severe among patients with TRS than in non-TRS cohorts. The pathophysiology of CD among people with TRS and efficacy of interventions to ameliorate CD among this cohort warrant greater scrutiny. [ABSTRACT FROM AUTHOR] |
| Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Given the robust association of cognitive deficits (CD) with community functioning in people with schizophrenia and the inconsistent findings from the limited research on CD among people with treatment-resistant schizophrenia (TRS), we evaluated the neurocognitive functions of patients with TRS. Methods: We retrospectively collated data on cognition and selected demographic and clinical variables of 181 patients with TRS and 59 with treatment-responsive schizophrenia (non-TRS) admitted to a psychiatric rehabilitation facility from 2010 to 2019. The Brief Assessment of Cognition in Schizophrenia (BACS) was used to evaluate cognitive function. Multivariate analysis was utilised to compare the BACS scores of the two groups. Results: TRS patients had more severe CD than non-TRS patients, with the BACS composite score (p =.003), verbal memory and learning (p =.003), working memory (p =.043), and psychomotor speed (p =.004) significantly worse in the TRS group. There was no significant difference in the BACS scores between the 60% of the TRS patients who were treated with clozapine and the TRS patients (40%) treated with other antipsychotics. Conclusion: CD are more severe among patients with TRS than in non-TRS cohorts. The pathophysiology of CD among people with TRS and efficacy of interventions to ameliorate CD among this cohort warrant greater scrutiny. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10398562 |
| DOI: | 10.1177/10398562251391697 |
